RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, today announced the acceptance of four presentations on the Company’s lead antibiotic drug candidate, PMX-30063, at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). ECCMID attracts more than ten thousand experts each year, covering key topics of infectious disease including diagnosis, prevention, pathogenesis, treatment, and antibiotic resistance. The meeting will take place in Milan, Italy from May 7-10, 2011. =news_view&newsId=20110505005304&newsLang=en
